Tumor Biology

, Volume 37, Issue 1, pp 817–822 | Cite as

The adaptor protein CrkII regulates IGF-1-induced biological behaviors of pancreatic ductal adenocarcinoma

  • Rui Liu
  • Qing Wang
  • Guangying Xu
  • Kexin Li
  • Lingli Zhou
  • Baofeng Xu
Original Article
  • 94 Downloads

Abstract

Recently, the adaptor protein CrkII has been proved to function in initiating signals for proliferation and invasion in some malignancies. However, the specific mechanisms underlying insulin-like growth factor 1 (IGF-1)-CrkII signaling-induced proliferation of pancreatic ductal adenocarcinoma (PDAC) were not unraveled. In this work, PDAC tissues and cell lines were subjected to in vitro and in vivo assays. Our findings showed that CrkII was abundantly expressed in PDAC tissues and closely correlated with tumor-node-metastasis (TNM) stage and invasion. When cells were subjected to si-CrkII, si-CrkII inhibited IGF-1-mediated PDAC cell growth. In vitro, we demonstrated the upregulation of CrkII, p-Erk1/2, and p-Akt occurring in IGF-1-treated PDAC cells. Conversely, si-CrkII affected upregulation of CrkII, p-Erk1/2, and p-Akt. In addition, cell cycle and in vivo assay identified that knockdown of CrkII inhibited the entry of G1 into S phase and the increase of PDAC tumor weight. In conclusion, CrkII mediates IGF-1 signaling and further balanced PDAC biological behaviors via Erk1/2 and Akt pathway, which indicates that CrkII gene and protein may act as an effective target for the treatment of PDAC.

Keywords

CrkII IGF-1 Proliferation Apoptosis PDAC 

Notes

Acknowledgments

This study was supported by grants to BFX from Foundation of Jilin Provincial Science & Technology Department [No. 201201044].

Conflicts of interest

None.

References

  1. 1.
    Song W, Li Q, Wang L, et al. FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma. Sci Rep. 2015;5:10081.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Aung KL, Moore MJ. Metformin for pancreatic cancer. Lancet Oncol. 2015;16(7):748–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Blanco VM, Latif T, et al. Imaging and therapy of pancreatic cancer with phosphatidylserine-targeted nanovesicles. Transl Oncol. 2015;8:196–203.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lamorte L, Royal I, Naujokas M, et al. Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. Mol Biol Cell. 2002;13:1449–61.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rodrigues SP, Fathers KE, Chan G, et al. CrkI and CrkII function as key signaling integrators for migration and invasion of cancer cells. Mol Cancer Res. 2005;3:183–94.PubMedGoogle Scholar
  6. 6.
    Iwahara T, Akagi T, Shishido T, et al. CrkII induces serum response factor activation and cellular transformation through its function in Rho activation. Oncogene. 2003;22:5946–57.CrossRefPubMedGoogle Scholar
  7. 7.
    Fathers KE, Rodrigues S, Zuo D, et al. CrkII transgene induces atypical mammary gland development and tumorigenesis. Am J Pathol. 2010;176:446–60.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hemmeryckx B, van Wijk A, Reichert A, et al. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice. Cancer Res. 2001;61:1398–405.PubMedGoogle Scholar
  9. 9.
    Matsuda M, Tanaka S, Nagata S, Kojima A, Kurata T, Shibuya M. Two species of human CRK cDNA encode proteins with distinct biological activities. Mol Cell Biol. 1992;12:3482–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Miller CT, Chen G, Gharib TG, et al. Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene. 2003;22:7950–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008;10:R25.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dickins RA, Hemann MT, Zilfou JT, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet. 2005;37:1289–95.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Rui Liu
    • 1
  • Qing Wang
    • 1
  • Guangying Xu
    • 2
  • Kexin Li
    • 3
  • Lingli Zhou
    • 1
  • Baofeng Xu
    • 4
  1. 1.Department of EndocrinologyChina-Japan Union Hospital of Jilin UniversityChangchunChina
  2. 2.Changchun Emergency CenterChangchunChina
  3. 3.Department of EndocrinologyPeople’s Hospital of Jilin ProvinceChangchunChina
  4. 4.Department of NeurosurgeryFirst Hospital of Jilin UniversityChangchunChina

Personalised recommendations